Olmesartan
CAS No. 144689-24-7
Olmesartan( RNH 6270 | CS 088 )
Catalog No. M11905 CAS No. 144689-24-7
An angiotensin II receptor antagonist which has been used for the treatment of high blood pressure.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 35 | In Stock |
|
| 50MG | 58 | In Stock |
|
| 100MG | 88 | In Stock |
|
| 500MG | 236 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOlmesartan
-
NoteResearch use only, not for human use.
-
Brief DescriptionAn angiotensin II receptor antagonist which has been used for the treatment of high blood pressure.
-
DescriptionAn angiotensin II receptor antagonist which has been used for the treatment of high blood pressure. Hypertension Discontinued(In Vitro):Olmesartan (0.7-5 mM; 24, 48 and 72 h) inhibits the growth of HeLa cells as a concentration- and time-dependent mode.(In Vivo):Repeated dosing of olmesartan (1 mg/kg, 2 mg/kg, p.o.) dose-dependently decreases mean arterial blood pressure (MAP) in SHR without significant influence on body weight and food intake during 10 weeks. Olmesartan (5 mg/kg/d, p.o.) and Hyd treatments lower systolic blood pressure to the same degree in mice. Olmesartan treatment inhibits cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression. Olmesartan treatment reverses decreased gene expressions of ACE2 and Mas receptor of Ren-Tg mice and inhibits enhanced NADPH oxidase (Nox)4 expression and reactive oxygen species.
-
In VitroOlmesartan (0.7-5 mM; 24, 48 and 72?h) inhibits the growth of HeLa cells as a concentration- and time-dependent mode. Cell Viability Assay Cell Line:Human cervical cancer cell line (HeLa) Concentration:0.7- 5 mM Incubation Time:24, 48 and 72?h Result:IC50s against HeLa cell line are 4.685 and 1.651 mM for 48 and 72 h, respectively.
-
In VivoRepeated dosing of olmesartan (1 mg/kg, 2 mg/kg, p.o.) dose-dependently decreases mean arterial blood pressure (MAP) in SHR without significant influence on body weight and food intake during 10 weeks. Olmesartan (5 mg/kg/d, p.o.) and Hyd treatments lower systolic blood pressure to the same degree in mice. Olmesartan treatment inhibits cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression. Olmesartan treatment reverses decreased gene expressions of ACE2 and Mas receptor of Ren-Tg mice and inhibits enhanced NADPH oxidase (Nox)4 expression and reactive oxygen species.
-
SynonymsRNH 6270 | CS 088
-
PathwayGPCR/G Protein
-
TargetAngiotensin Receptor
-
RecptorAngiotensin Receptor
-
Research AreaCardiovascular Disease
-
IndicationHypertension
Chemical Information
-
CAS Number144689-24-7
-
Formula Weight446.5016
-
Molecular FormulaC24H26N6O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 55 mg/mL
-
SMILESO=C(C1=C(C(C)(O)C)N=C(CCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)O
-
Chemical Name1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mizuno M, et al. Eur J Pharmacol. 1995 Oct 16;285(2):181-8.
2. Kim S, et al. Hypertens Res. 1997 Jun;20(2):133-42.
3. Takemoto M, et al. Hypertension. 1997 Dec;30(6):1621-7.
molnova catalog
related products
-
Losartan
A selective, competitive angiotensin II receptor type 1 (AT1) antagonist (IC50=20 nM) for treatment of high blood pressure (hypertension).
-
Sparsentan
Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively.
-
Angiotensin 1-7
Angiotensin (1-7) (Ang-(1-7)) is an active heptapeptide of the Renin-angiotensin system (RAS).
Cart
sales@molnova.com